Recalled BD PosiFlush Heparin Syringes, Saline Syringes Linked to Serratia Marcescens Bloodstream Infections

Earlier this year, Becton Dickinson (BD) recalled a number of herparin flush syringes and pre-filled saline syringes, which have been linked to reports of Serratia marcenscens bacterium infections; which can cause serious and life-threatening health complications, especially for already ill children. 

The BD PosiFlush heparin syringe and BD Pre-Filled Normal Saline Syringe recall was originally issued in April 2018, after the U.S. Centers for Disease Control and Prevention (CDC) linked the syringes to at least 14 serious bloodstream infections among children in four different states.

The illnesses occurred in Tennessee, Colorado, Minnesota and Ohio, according to the CDC. The illnesses occurred among seriously ill children who were given the drugs through intravenous injections through a catheter central line. No deaths have been linked to the infections, and the CDC said in May that the illnesses appeared to be winding down.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The recalled syringes include 21 lots of BD PosiFlush Heparin Lock Flush Syringes with catalog numbers 306509, 306510, 306511, 306512, 306513, 306514, 306515, 306516, 306517, 306521, 306525, 306528, and 306531 and BD Pre-Filled Normal Saline Syringes with catalog numbers 306500, 306502, 306503, 306504, 306505, 306507, 306508, and 306518.

BD asked healthcare professionals to check their inventories for the catalog and lot numbers listed in the recall and to quarantine the products subjected to the recall.

Heparin, derived mainly from pig intestines, has been linked in past years to serious contamination events. FDA investigations found that heparin sold throughout the United States during late 2007 and early 2008 contained a replacement ingredient known as oversulfated chondroitnin sulfate, which should not be in the drug. The contaminated heparin ingredients were produced at a plant in China. The substitute chemical is substantially cheaper than heparin and was linked to numerous allergic reactions and a number of lawsuits.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A federal judge has scheduled a series of case management conferences throughout 2026 as the parties prepare for five “pilot” bellwether trials, which are expected to begin in late 2026 or early 2027.
An increasing number of Ozempic and Mounjaro users are reporting sudden, irreversible vision loss from NAION side effects, prompting new lawsuits and a federal push to consolidate blindness claims into a dedicated multidistrict litigation.
Cartiva is urging federal judges to reject consolidation of toe-implant lawsuits, arguing that an MDL would interfere with individual claim resolutions that the company says are already being handled efficiently outside of court.